

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001682019
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer CRISPR THERAPEUTICS AG
SEC File Number 001-37923
Address of Issuer Baarerstrasse 14
Zug
SWITZERLAND
6300
Phone 41-41-561-32-77
Name of Person for Whose Account the Securities are To Be Sold Dr. Samarth Kulkarni

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	75000	4114500	85353479	11/11/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from	Is this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	---------------------	---------	---------------------	-------------------------------	-----------------	---------------------

			Whom Acquired	a Gift?		
Common	03/01/2021	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	868	03/01/2021 Compensation
Common	12/01/2020	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	888	12/01/2020 Compensation
Common	09/01/2021	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	880	09/01/2021 Compensation
Common	03/10/2021	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	6307	03/10/2021 Compensation
Common	06/01/2021	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	888	06/01/2021 Compensation
Common	09/01/2020	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	888	09/01/2020 Compensation
Common	12/01/2021	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	888	12/01/2021 Compensation
Common	12/01/2019	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	926	12/01/2019 Compensation
Common	12/03/2021	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	42182	12/03/2021 Compensation
Common	06/01/2020	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	887	06/01/2020 Compensation
Common	03/10/2022	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	6347	03/10/2022 Compensation
Common	03/11/2022	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	4847	03/11/2022 Compensation
Common	02/18/2023	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	2605	02/18/2023 Compensation
Common	12/03/2022	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	336	12/03/2022 Compensation
Common	12/03/2022	Acquired as compensation -- Restricted Stock Awards	Issuer	<input type="checkbox"/>	5263	12/03/2022 Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 6/13/2024 that is intended to comply with Rule 10b5-1(c). Filing intended to be made on 11/11/2024. Unable to be submitted due to federal holiday.
Date of Notice	11/12/2024
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/13/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Goldman Sachs & Co. LLC on behalf of Samarth Kulkarni

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)